{
    "nctId": "NCT00700778",
    "briefTitle": "Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations",
    "officialTitle": "Genomic Markers of Breast Cancer Prevention Induced by HCG in Women at High Risk",
    "overallStatus": "TERMINATED",
    "conditions": "BRCA1 Mutation, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Measurement of Gene Expression in Breast Epithelial Cells Obtained for Asymptomatic High Breast Cancer Risk Nulliparous Premenopausal Women at Baseline, After Treatment With r-hCG at 90 Days, and at 270 Days From Baseline",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Asymptomatic women who have a deleterious mutation on the BRCA1 gene\n* Normal, no complaints, no evidence of disease\n* Nulliparous, never pregnant (G0P0)\n* No previous diagnosis of breast or ovarian cancer\n* No known brain metastases\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status (PS) 0-1 OR Karnofsky PS 90-100%\n* Premenopausal with normal menstrual cycles and intact ovaries\n* Normal ovarian size report from pelvic ultrasound\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective barrier contraception\n* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to human chorionic gonadotropin preparations or one of its excipients\n* No uncontrolled intercurrent illness including any of the following:\n\n  * Ovarian enlargement of undetermined origin\n  * Ovarian cysts \\> 2 cm\n  * Microcystic ovaries, which might predispose to the development of ovarian hyperstimulation syndrome\n  * History of prior cancer other than non-melanoma skin cancer\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Severe cognitive deficit or psychiatric illness/social situations that would make her unable to give informed consent or would limit compliance with study requirements\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 6 weeks since prior and no concurrent oral contraceptives or hormone-replacement therapy\n* No concurrent tamoxifen for chemoprevention\n* No concurrent participation in another chemopreventive trial for breast cancer\n* No concurrent medication that could interfere with this study including any of the following:\n\n  * Hormonal contraceptives\n  * Androgens\n  * Prednisone\n  * Thyroid hormones\n  * Insulin\n* No other concurrent investigational agents\n* No recent treatment with follicle-stimulating hormone for assisted reproduction\n* No HIV-positive patients on concurrent combination antiretroviral therapy",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT"
}